Literature DB >> 15327755

Intima-media thickness of the carotid arteries is related to serum osteoprotegerin levels in healthy postmenopausal women.

Bulent Erdogan1, Erdogan Aslan, Tayfun Bagis, Adnan Gokcel, Serkan Erkanli, Murad Bavbek, Nur Altinors.   

Abstract

Osteoprotegerin (OPG) regulates bone mass by inhibiting osteoclast differentiation and activation, and also plays a role in vascular calcification. The objective of this study was to evaluate the relationship between serum OPG levels, and carotid artery intima-media thickness (IMT) and carotid plaque formation in healthy postmenopausal women. We recruited 68 healthy postmenopausal women for the study. Carotid plaque presence and IMT were evaluated by high resolution B-mode ultrasound. IMT was positively correlated with presence of plaque, age, menopause age and OPG, and inversely correlated with Apolipoprotein A1 (Apo A1). Serum OPG level was positively correlated with IMT (r = 0.366; p < 0.003) and age (r = 0.324; p < 0.008), and negatively correlated with Apo A1 (r = -0.481; p < 0.0001). We did not observe any significant relation between plaque occurrence and levels of serum OPG. In regression analysis OPG (p < 0.02) and menopause age (p < 0.05) were independent risk factors for IMT, and age (p < 0.05) and IMT (p < 0.05) were independent risk factors for plaque formation. Although the role of OPG in the vascular biology is poorly understood, our results suggest that elevated levels of serum OPG is associated with IMT and may play a role in the pathogenesis of atherosclerotic disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15327755     DOI: 10.1179/016164104225014157

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  7 in total

1.  Effect of lifestyle interventions with or without metformin therapy on serum levels of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in patients with prediabetes.

Authors:  Muyesser Sayki Arslan; Esra Tutal; Mustafa Sahin; Melia Karakose; Bekir Ucan; Gulfer Ozturk; Erman Cakal; Zeynep Biyikli Gencturk; Mustafa Ozbek; Tuncay Delibasi
Journal:  Endocrine       Date:  2016-10-15       Impact factor: 3.633

2.  Serum osteoprotegerin: bone or cardiovascular marker in Type 2 diabetes males?

Authors:  P Rozas Moreno; R Reyes García; A García-Martín; M Varsavsky; J A García-Salcedo; M Muñoz-Torres
Journal:  J Endocrinol Invest       Date:  2012-02-28       Impact factor: 4.256

3.  Carotid intima-media thickness and bone turnover: the role of C-terminal telopeptide of type I collagen.

Authors:  Christian Leli; Leonella Pasqualini; Gaetano Vaudo; Stefano Gaggioli; Anna Maria Scarponi; Elmo Mannarino
Journal:  Intern Emerg Med       Date:  2010-02-25       Impact factor: 3.397

4.  Bone mineral density and atherosclerosis: the Multi-Ethnic Study of Atherosclerosis, Abdominal Aortic Calcium Study.

Authors:  Joseph A Hyder; Matthew A Allison; Elizabeth Barrett-Connor; Robert Detrano; Nathan D Wong; Claude Sirlin; Susan M Gapstur; Pamela Ouyang; J Jeffrey Carr; Michael H Criqui
Journal:  Atherosclerosis       Date:  2009-09-12       Impact factor: 5.162

5.  Association of coronary artery and aortic calcium with lumbar bone density: the MESA Abdominal Aortic Calcium Study.

Authors:  Joseph A Hyder; Matthew A Allison; Nathan Wong; Agnes Papa; Thomas F Lang; Claude Sirlin; Susan M Gapstur; Pamela Ouyang; J Jeffrey Carr; Michael H Criqui
Journal:  Am J Epidemiol       Date:  2008-12-08       Impact factor: 4.897

Review 6.  Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

Authors:  Ann E Kearns; Sundeep Khosla; Paul J Kostenuik
Journal:  Endocr Rev       Date:  2007-12-05       Impact factor: 19.871

7.  Associations of fetuin-A and osteoprotegerin with arterial stiffness and early atherosclerosis in chronic hemodialysis patients.

Authors:  Panagiotis Pateinakis; Aikaterini Papagianni; Stella Douma; Georgios Efstratiadis; Dimitrios Memmos
Journal:  BMC Nephrol       Date:  2013-06-12       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.